Papers from every journal, all in one place. Create custom feeds.
Equips clinicians with a diagnostic framework for pediatric cardiogenic shock; leaves open prospective validation of outcomes.

Clinicians should integrate extracranial bleeding risk into OAC decisions for AF; this meta-analysis extends trial data by quantifying baseline factors' contribution to most attributable risk.

Medical News Publication, MedXY
This large-scale pooled analysis robustly confirms that extracranial bleeding is a common and clinically meaningful complication in AF patients receiving OAC therapy. The differentiation between major and nonmajor bleeding using standardized ISTH criteria lends uniformity and reproducibility to event adjudication. The predominance of gastrointestinal bleeding among major extracranial bleeds aligns with prior clinical observations, underscoring the importance of GI risk assessment and management (e.g., Helicobacter pylori screening, proton pump inhibitors) in anticoagulated patients.
MRAs reduce CV events similarly in Black and non-Black HF patients; confirms consistent efficacy across races and supports broad use.

May support MACE reduction with tirzepatide in T2D and ASCVD; hypothesis-generating and leaves open need for RCTs.

Resident Physician in the Department of Cardiovascular Diseases, TUM University Hospital
The data on infections surprised us because the findings were so striking. In addition, significantly fewer patients treated with tirzepatide had infections requiring hospital admission: the associated risk was reduced by 36 percent. The risk of infection-related death was reduced by as much as 60 percent.
LV dimension may refine HF mortality risk stratification beyond LVEF; leaves open whether it should guide therapy.

Cardiologist, Chinese Cardiovascular Association
A U-shaped association emerged between LV dimension and mortality; both abnormally small and large ventricles were independently associated with increased all-cause and cardiovascular mortality, with particularly strong associations observed in younger patients. The presence of either an abnormal LV or systolic dysfunction, whether independently or in combination, was associated with an elevated mortality risk in patients with HF.
May support ISO-CVi for VT risk stratification in TOF; leaves open superiority to EGM-CVi pending prospective validation.

Current SAQ-SS most strongly predicts events; extends serial monitoring value for risk stratification in chronic coronary disease.

Supports PREVENT use for contemporary US risk estimation; extends validation to large EHR cohorts but leaves adoption open pending trials.

Cardiology, Aga Khan University
Risk equations are useful only insofar as they estimate risk accurately in the settings in which treatment decisions are made. Their real test is calibration in contemporary, heterogeneous populations, particularly when estimates are used to initiate therapies, communicate prognosis, and allocate preventive resources. The American Heart Association Predicting Risk of Cardiovascular Disease Events (PREVENT) equations were designed for this changing landscape.
CRT-D associated with lower mortality than CRT-P in NICM; leaves open whether defibrillator benefit holds in randomized trials.

SMuRF burden may refine risk stratification beyond TPD on SPECT; leaves open need for prospective validation before altering practice.
